

xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 1 of 17

Complying with Regulation (EC) No 1272/2008 (CLP) as amended by Commission Regulation (EU) 2020/878. (Luxembourg)

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Product name: xTAG® Cystic Fibrosis (CFTR) 71 kit v2,

Other means of identification:

Commercial name(s): xTAG® Cystic Fibrosis (CFTR) 71 kit v2

Product Codes: 1024C0185

1.2 Relevant identified uses of the substance or mixture and uses advised against:

Relevant identified uses: For Professional use only. Use as per Product Insert

Uses advised against: Uses other than those described above.

1.3 Details of the supplier of the safety data sheet

Company Name: Luminex Molecular Diagnostics, Inc.

Company Address: 439 University Avenue,

Toronto, Ontario, Canada, M5G 1Y8

Company Tel (Enquiries): Tel: 1- (512) 381-4397

Toll Free: 1-(877)-785-2323 (US and Canada)

Fax: (512) 219-5114

http://www.luminexcorp.com

1.4 Emergency telephone number

Emergency telephone number (including hours of operation): 1-(512) 381-4397

Emergency email: support@luminexcorp.com

Hours of operations: 24/7

Poison Centre Information:

070 245 245

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Classification in accordance to Regulation (EC) No. 1272/2008 (CLP/GHS)

Overall Classification for the kit:

Product name	GHS Classification
xTAG [®] Cystic Fibrosis (CFTR) 71 kit v2	Not classified as hazardous

Classification of BOX 1:

Not classified as hazardous

Classification of the components of BOX 1:

Component 1: xTAG® CFTR PCR Mix v2

Not classified as hazardous



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

109 January 2024

Page 2 of 17

Component 2: xTAG® CFTR Bead Mix A v2

Not classified as hazardous

Component 3: xTAG® CFTR Bead Mix B v2

Not classified as hazardous

Component 4: xTAG® CFTR ASPE Mix A v2

Not classified as hazardous

Component 5: xTAG® CFTR ASPE Mix B v2

Not classified as hazardous

Component 6: xTAG® Reporter Buffer

Not classified as hazardous

Component 7: Platinum® Tfi Exo(-) DNA Polymerase

Not classified as hazardous

Component 8: Platinum® Tfi Reaction Buffer, 5x

Skin irritation, category 2 Eye irritation, category 2

Component 9: Platinum® Tfi 50mM MgCl₂

Not classified as hazardous

Component 10: xTAG® Shrimp Alkaline Phosphatase

Not classified as hazardous

Component 11: xTAG® Exonuclease I

Not classified as hazardous

Classification of the components of BOX 2:

Component 12: xTAG Streptavidin, R-Phycoerythrin Conjugate

Not classified as hazardous

2.2 Label elements

Labelling in accordance with Regulation 1272/2008

Labelling information for the kit:

Hazard pictograms:
Signal word:
None required
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Labelling information for BOX 1:

Hazard pictograms:
Signal word:
None required
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 3 of 17

Labelling information for the components of the kit:

Component 1: xTAG® CFTR PCR Mix v2

Hazard pictograms:
Signal word:
Hazard statements:
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Component 2: xTAG® CFTR Bead Mix A v2

Hazard pictograms:
Signal word:
None required
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Component 3: xTAG® CFTR Bead Mix B v2

Hazard pictograms:
Signal word:
None required
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Component 4: xTAG® CFTR ASPE Mix A v2

Hazard pictograms:
Signal word:
Hazard statements:
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Component 5: xTAG® CFTR ASPE Mix B v2

Hazard pictograms:
Signal word:
Hazard statements:
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Component 6: xTAG® Reporter Buffer

Hazard pictograms: None required Signal word: None required Hazard statements: None required Precautionary Statements: None required



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 4 of 17

Supplemental Hazard

Statements. None known

Component 7: Platinum® Tfi Exo(-) DNA Polymerase

Hazard pictograms:
Signal word:
None required
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Component 8: Platinum® Tfi Reaction Buffer, 5x

Hazard pictograms:



Signal word: WARNING

Hazard statements: H315 – Causes skin irritation

H319 – Causes serious eye irritation

Precautionary Statements: P264 - Wash thoroughly after handling

P280 - Wear protective gloves/protective clothing/eye protection/face

protection.

P302+P352 - IF ON SKIN: Wash with plenty of water.

P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue

rinsing.

P332+P313 - If skin irritation occurs: Get medical advice/attention P337+P313 - If eye irritation persists: Get medical advice/attention

Supplemental Hazard

Statements. None known

Component 9: Platinum® Tfi 50mM MgCl₂

Hazard pictograms: None required None required Hazard statements: None required Precautionary Statements: None required

Supplemental Hazard

Statements. None known

Component 10: xTAG® Shrimp Alkaline Phosphatase

Hazard pictograms:None requiredSignal word:None requiredHazard statements:None requiredPrecautionary Statements:None required



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 5 of 17

Supplemental Hazard

Statements. None known

Component 11: xTAG® Exonuclease I

Hazard pictograms:
Signal word:
None required
None required
None required
None required
None required
None required

Supplemental Hazard

Statements. None known

Labelling information for BOX 2:

Component 12: xTAG® Streptavidin, R-Phycoerythrin Conjugate

Hazard pictograms: None required None required Hazard statements: None required Precautionary Statements: None required

Supplemental Hazard

Statements. None known

2.3 Other hazards

This substance/mixture contains Poly(oxy-1,2-ethanediyl), α -[(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxy-which is considered to be an endocrine-disrupting substance at levels below 0.1%..

No components are classified as persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1Substances:

Not applicable

3.2 Mixture:

Component 1: xTAG® CFTR PCR Mix v2:

Not classified as a hazardous mixture and therefore does not require reporting in this section.

Component 2: xTAG® CFTR Bead Mix A v2:

Product/ Ingredient name	Identifiers	%	Classification 1272/2008/EC	Nano material form	M Factor	Specific conc'n limits (SCL)	Acute toxicity estimate (ATE)
Poly(oxy- 1,2- ethanediyl), α-[4-(1,1,3,3- tetramethylb utyl)phenyl]- ω-hydroxy-	CAS No 9002-93-1 EC No 618-344-0 REACH No n/a	< 0.1%	Acute Tox. 4, (oral) H302 Skin Irrit 2 H315 Eye Dam 1, H318 Aquatic Chronic 2, H411	No	1	No SCL in Annex VI	No ATE in Annex VI



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 6 of 17

Component 3: xTAG® CFTR Bead Mix B v2:

Product/ Ingredient name	Identifiers	%	Classification 1272/2008/EC	Nano material form	M Factor	Specific conc'n limits (SCL)	Acute toxicity estimate (ATE)
Poly(oxy- 1,2- ethanediyl), α-[4-(1,1,3,3- tetramethylb utyl)phenyl]- ω-hydroxy-	CAS No 9002-93-1 EC No 618-344-0 REACH No n/a	< 0.1%	Acute Tox. 4, (oral) H302 Skin Irrit 2 H315 Eye Dam 1, H318 Aquatic Chronic 2, H411	No	1	No SCL in Annex VI	No ATE in Annex VI

Component 4: xTAG® CFTR ASPE Mix A v2:

Not classified as a hazardous mixture and therefore does not require reporting in this section.

Component 5: xTAG® CFTR ASPE Mix A v2:

Not classified as a hazardous mixture and therefore does not require reporting in this section.

Component 6: xTAG® Reporter Buffer

Product/ Ingredient name	Identifiers	%	Classification 1272/2008/EC	Nano material form	M Factor	Specific conc'n limits (SCL)	Acute toxicity estimate (ATE)
Poly(oxy- 1,2- ethanediyl), α-[4-(1,1,3,3- tetramethylb utyl)phenyl]- ω-hydroxy-	CAS No 9002-93-1 EC No 618-344-0 REACH No n/a	< 0.1%	Acute Tox. 4, (oral) H302 Skin Irrit 2 H315 Eye Dam 1, H318 Aquatic Chronic 2, H411	No	1	No SCL in Annex VI	No ATE in Annex VI

Component 7: Platinum[®] *Tfi* Exo(-) DNA Polymerase
Not classified as a hazardous mixture and therefore does not require reporting in this section.

Component 8: Platinum® Tfi Reaction Buffer, 5x

Product/ Ingredient name	Identifiers	%	Classification 1272/2008/EC	Nano material form	M Factor	Specific conc'n limits (SCL)	Acute toxicity estimate (ATE)
Potassium hydroxide	CAS No 1310-58-3 EC No 215-181-3 REACH No 01- 2119487136 -33-XXXX	0.1-1.5%	Acute Tox. 4, (oral) H302 Skin Irrit 1A H314	No	1	Skin Corr 1A H314: C ≥ 5% Skin Corr 1B H314: 2 ≤ C < 5% Skin Irrit. 2 H315: 0.5 ≤ C < 2% Eye Irrit. 2; H319 0.5 ≤ C < 2%	No ATE in Annex VI



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 7 of 17

Component 9: Platinum® Tfi 50mM MgCl₂:

Not classified as a hazardous mixture and therefore does not require reporting in this section.

Component 10: xTAG® Shrimp Alkaline Phosphatase:

Not classified as a hazardous mixture and therefore does not require reporting in this section.

Component 11: xTAG® Exonuclease I:

Product/ Ingredient name	Identifiers	%	Classification 1272/2008/EC	Nano material form	M Factor	Specific conc'n limits (SCL)	Acute toxicity estimate (ATE)
2- Mercapto ethanol	CAS No 60-24-2 EC No 215-181-3 REACH No 01- 2119487136- 33-XXXX	0.01-0.1%	Acute Tox 3 (oral) H301 Acute Tox 2 (dermal) H310 Skin Irrit 2 H315 Skin Sens 1A H317 Eye Dam 1 H318 Acute Tox 3 (inhal) H331 Repr 2 H361 STOT RE 2 H373 Aquatic acute 1 H400 Aquatic chronic 2 H411	No	1	No SCL in Annex VI	No ATE in Annex VI

Component 12: xTAG® Streptavidin, R-Phycoerythrin Conjugate:

Not classified as a hazardous mixture and therefore does not require reporting in this section.

Nanoforms present in product: Not applicable

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in section 8 . See section 16 for the full text of the H and P statements declared above

SECTION 4: FIRST AID MEASURES

Eye contact: In case of eye contact, remove contact lenses and rinse immediately with plenty of

water, including under the eyelids, for at least 15 mins. Get medical attention if

symptoms develop.

Skin contact: Wash with water and soap and rinse thoroughly. Seek medical advice if irritation or

pain develops.

Inhalation: Move affected person to fresh air and keep warm and at rest in a position

comfortable for breathing. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Oxygen should only be administered by qualified personnel.

Seek medical advice.



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 8 of 17

Do NOT induce vomiting. Get medical attention immediately. If spontaneous Ingestion:

vomiting occurs, keep head below hips to avoid breathing the product into the lungs.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Overall Kit: None known Box 1: None known **Box 2:** None known

Component 1: xTAG® CFTR PCR Mix v2: None known Component 2: xTAG® CFTR Bead Mix A v2: None known Component 3: xTAG® CFTR Bead Mix B v2: None known Component 4: xTAG® CFTR ASPE Mix A v2: None known Component 5: xTAG® CFTR ASPE Mix B v2: None known Component 6: xTAG® Reporter Buffer: None known

Component 7: Platinum® Tfi Exo(-) DNA Polymerase: None known Component 8: Platinum® Tfi Reaction Buffer, 5x: Causes skin irritation. Causes serious eye irritation.

Component 9: Platinum® Tfi 50mM MgCl₂: None known

Component 10: xTAG® Shrimp Alkaline Phosphatase: None known

Component 11: xTAG® Exonuclease I: None known

Component 12: xTAG® Streptavidin,

R-Phycoerythrin Conjugate: None known

4.3 Indication of any immediate medical attention and special treatment needed

If any symptoms are observed, contact a physician and give them this SDS sheet. Provide general supportive measures and treat symptomatically:

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media: In case of fire: Use water spray (fog), carbon dioxide (CO2), dry chemical powder or foam to extinguish. Use an extinguishing agent suitable for the surrounding area. Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

No specific fire or explosion hazard.

Hazardous combustion products:

Carbon dioxide, carbon monoxide, metal oxide/oxides.

5.3 Advice for firefighters

Move containers from fire area if you can do it without risk. Cool containers with flooding quantities of water until well after fire is out. Isolate the hazard area and deny entry to unnecessary and unprotected personnel. Keep out of drains, sewers, ditches and waterways. Inhalation is a health risk. Firefighters should wear selfcontained breathing apparatus and full firefighting turnout gear. Wear self-contained breathing apparatus and protective clothing. In addition, wear other appropriate protective equipment as conditions warrant (see Section 8).

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

No action shall be taken involving any personal risk or without suitable training. Keep unnecessary and unprotected personnel from entering.



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 9 of 17

For emergency responders

For large spillages, evacuate the area of all non-essential personnel. Ventilate contaminated area thoroughly. Avoid contact with spilled or released material. Immediately remove all contaminated clothing. Stay upwind and away from spill/release.

Wear appropriate protective equipment, such as gloves, goggles and protective clothing, as conditions warrant (see Section 8).

See Sections 2 and 7 for additional information on hazards and precautionary measures.

See Section 13 for disposal guidance.

6.2 Environmental precautions

Avoid disposal of spilt material and runoff and contact with soil, waterways, drains and sewers. May be harmful to the environment if released in large quantities. Collect spillage.

6.3 Methods and materials for containment and cleaning up

Dilute with water and mop up if water-soluble or absorb with an inert dry material and place in an appropriate waste disposal container.

6.4 Reference to other sections

See Section 1 for emergency contact information.

See Section 7 for information on safe handling.

See Section 8 for information on personal protection equipment.

See Section 13 for disposal informa+tion.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Use only with adequate ventilation. Wear appropriate personal protective equipment and use exposure controls as indicated in Section 8. Avoid contact with skin and eyes. Avoid breathing product dust or vapours. Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations.

Storage temperature:

Component 1-11 Store at -25°C to -15°C.

Component 12: Store at 2°C to 6°C.

7.3 Specific end use(s):

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated.

SECTION 8: EXPOSURE CONTROL / PERSONAL PROTECTION

8.1 Control parameters

Occupational exposure limit values:

Ingredient name	CAS Number	Occupational exposure limits	Source
Poly(oxy-1,2-ethanediyl), α-[4-(1,1,3,3- tetramethylbutyl)phenyl]- ω-hydroxy-	9002-93-1	Short-term value: None known Long-term value: None known	Europe Occupational Exposure Limit Values



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 10 of 17

Ingredient name	CAS Number	Occupational exposure limits	Source
Potassium hydroxide	1310-58-3	Short-term value: None known Long-term value: None known	Europe Occupational Exposure Limit Values
2-Mercaptoethanol	60-24-2	Short-term value: None known Long-term value: None known	Europe Occupational Exposure Limit Values

Monitoring procedures: Use methods described in European Standards.

Derived No Effect Level (DNEL):

Poly(oxy-1,2-ethanediyl), α -[4-(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxy-

None known

Potassium hydroxide

Workers	Inhalation	Long-term local effects	1 mg/m3
General population	Inhalation	Long-term local effects	1 mg/m3

2-Mercaptoethanol

Workers	Inhalation	Long-term systemic effects	0.17 mg/m3
Workers	Inhalation	Short-term systemic effects	0.17 mg/m3
Workers	Dermal	Long-term systemic effects	0.05 mg/kg bw/day
Workers	Dermal	Short-term systemic effects	0.05 mg/kg bw/day
General population	Oral	Long-term systemic effects	0.025 mg/kg bw/day
General population	Oral	Short-term systemic effects	0.025 mg/kg bw/day

Predicted No Effect Concentration (PNEC):

Poly(oxy-1,2-ethanediyl), α -[4-(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxy- (Plug 4)

None known

Potassium hydroxide

No data available: testing technically not feasible

2-Mercaptoethanol

Component	Value
Fresh water	0.006 mg/L
Marine water	0.001 mg/L
Sewage treatment plant	60 mg/L
Fresh water sediment	0.024 mg/kg sediment dw
Marine sediment	0.002 mg/kg sediment dw
Soil	0.908 mg/kg soil dw

8.2 Exposure controls

Appropriate Engineering Measures

No special ventilation requirements. Apply technical measures to comply with the occupational exposure limits. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Ensure adequate ventilation to keep airborne concentrations low. Do not empty waste into water drains.



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 11 of 17

Individual protection measures, such as personal protective equipment:

Eye and face protection: Not required under normal conditions of use.

Skin protection:

Hand protection: Not required under normal conditions of use.

Other skin protection: Not required under normal conditions of use. Wash hands after use.

Respiratory protection: Not required under normal conditions of use.

Thermal hazards: None known.

Environmental exposure controls: Prevent further leakage or spillage if safe to do so. Prevent product from entering drains or water systems.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Physical State: Liquid (all components)

Colour: Colourless (components 1 - 11)

Light pink (component 12)

Odour and odour threshold: Odourless (all components)

Melting point/Freezing point: Not available

Boiling point or initial boiling

point and boiling range: Not available Flammability: Not available

Lower and upper explosion limit::

Lower (%):
Upper (%):
Not available
Not available

Flash point: Not available Auto-ignition temperature: Not available Decomposition temperature: Not available

pH: Component 8. 6 to 8

Kinematic viscosity: Not available Solubility: Not available.

Partition coefficient

n-octanol/water (log value):
Vapour pressure:
Density and/or relative density:
Relative vapour density:
Decomposition temperature:
Particle characteristics:

Not available
Not available
Not available
Not available

9.2 Other information:

Information with Regard to

Physical Hazard Classes: None known Other Safety Characteristics: None known

SECTION 10: STABILITY AND REACTIVITY



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 12 of 17

10.1 Reactivity

No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability

All components are stable under normal conditions.

10.3 Possibility of hazardous reactions

Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid

None known

10.5 Incompatible materials

Reactive or incompatible with the following materials: oxidizing materials.

10.6 Hazardous Decomposition products:

Under normal conditions of storage and use, hazardous decomposition products should not be produced

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity: None expected

Product/ingredient name	Test	Species	Dose
Poly(oxy-1,2-ethanediyl), α-[4- (1,1,3,3- tetramethylbutyl)phenyl]-ω- hydroxy-	LD50 Oral LD50 Dermal LC50 Inhalation	Rat Rabbit Rat	None known None known None known
Potassium hydroxide	LD50 Oral	Rat	333 mg/kg
	LD50 Dermal	Rabbit	None known
	LC50 Inhalation	Rat	None known
2-Mercaptoethanol	LD50 Oral	Rat	336 mg/kg
	LD50 Dermal	Rabbit	112 – 224 mg/kg
	LC50 Inhalation	Rat	2 mg/L 4h

Skin corrosion/irritation: Causes skin irritation (component 8)

Serious eye damage/eye irritation: Causes serious eye irritation (component 8)

Respiratory or skin sensitization: Not expected to cause respiratory sensitization. Not expected to

cause skin sensitization or allergic reaction.

Germ cell mutagenicity: This product is not expected to cause genetic defects.

Carcinogenicity: This product is not expected to cause cancer.

Reproductive toxicity: Not expected to cause damage to fertility or the unborn child.

STOT – Single exposure: This product is not expected to cause specific target

organ toxicity after a single exposure

STOT – Repeat exposure: This product is not expected to cause specific target

organ toxicity after prolonged or repeated exposure.

Aspiration hazard: Not expected to cause an aspiration hazard.

11.2 Information on other hazards:

Endocrine disrupting properties: Poly(oxy-1,2-ethanediyl), α -[(1,1,3,3-tetramethylbutyl)phenyl]- ω -



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 13 of 17

hydroxy- is classified as having endocrine disrupting properties and is on the Candidate List of substances of very high concern.

Information on other hazards: None known.

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity:

Substance name	Toxicity to fish / other aquatic invertebrates
Poly(oxy-1,2-ethanediyl), α-[4- (1,1,3,3-tetramethylbutyl)phenyl]-ω- hydroxy-	Fish - LC50 Pimephales promelas 4 - 8.9 mg/l 96 h Invertebrates - EC50 Daphnia magna 18 - 26 mg/L 48 h
Potassium hydroxide	None knowm
2-Mercaptoethanol	Fish – LC50 Leuciscus idus 37 mg/L 96h Invertebrates - EC50 Daphnia magna 0.4 mg/L 48h Algae – EC50 Desmodesmus subspicatus 19 mg/L 72h

12.2 Persistence and Degradability:

No data available for this product

12.3 Bioaccumulative potential:

No data available for this product

12.4 Mobility in soil:

No data available for this product

12.5 Results of PBT and vPvB assessment:

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Poly(oxy-1,2-ethanediyl), α -[(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxy- is classified as having endocrine disrupting properties and is on the Candidate List of substances of very high concern.

12.7 Other adverse effects:

None known.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods:

Methods of disposal

The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous Waste

The classification of the product may NOT meet the criteria for a hazardous waste.

Contaminated packaging - methods of disposal

The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered where recycling is not feasible.



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 14 of 17

Special precautions

This material and its container must be disposed of in a safe way. Care should be taken when handling empty containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid disposal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: TRANSPORT INFORMATION

International transport regulations

14.1 <u>UN number:</u>

ADR/RID/ADN: Not applicable IMDG: Not applicable IATA: Not applicable

14.2 Proper shipping name:

ADR/RID/ADN: Not regulated as hazardous for transport

IMDG: Not regulated as hazardous for transport

<u>IATA:</u> Not regulated as hazardous for transport

14.3 Transport hazard class(es)

ADR/RID/ADN: n/a IMDG: n/a IATA: n/a

14.4 Packing group

ADR/RID/ADN: n/a IMDG: n/a IATA: n/a

14.5 Environmental hazard

Marine Pollutant: Not expected

Additional information:

ADR/RID/ADN: Limited Quantity – not applicable

IATA: Limited Quantity – not applicable

IMDG: Limited Quantity – not applicable

14.6 Special precautions for user

Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO instruments

Not applicable

Section 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

This safety datasheet complies with the requirements of:

EU Commission Regulation (EU) 2020/878 (REACH)

EU Regulation (EC) No 1272/2008 (CLP)

<u>EINECS</u>: All components in this product are listed on the European Inventory of Existing Chemical Substance



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 15 of 17

Annex XIV - List of substances subject to authorisation

Intrinsic property	Ingredient Name	Status	Reference number	Date of revision
Substance of equivalent concern for environment	Poly(oxy-1,2-ethanediyl), α- [(1,1,3,3-tetramethylbutyl) phenyl]-ω-hydroxy-	Listed	42	Sunset date 2021-01-04 – IVD exempted as SR&D activity

German Ordinance on Facilities Handling Substances that are Hazardous to Water (Verordnung über Anlagen zum Umgang mit wassergefährdenden Stoffen (AwSV)):

CHEMICAL	Identification number	WGK (Water hazard class)
Poly(oxy-1,2-ethanediyl), α-[4- (1,1,3,3-tetramethylbutyl)phenyl]- ω-hydroxy-	8602	WGK 2
Potassium hydroxide (Kaliumhydroxid)	345	WGK 1
2-Mercaptoethanol	884	WGK 3
PRODUCT		WGK 2

NWG - non-hazardous to water

WGK1 - slightly hazardous to water

WGK2 - obviously hazardous to water

WGK3 - highly hazardous to water.

Substances that are currently not published with a WGK classification in the Bundesanzeiger must be regarded as highly hazardous to water (WGK 3) for reasons of precaution.

15.2 Chemical safety assessment

For this product a chemical safety assessment was not carried out on this product.

Section 16: OTHER INFORMATION

Full text of H and P-Statements referred to under sections 2 and 3.

Acute Tox
Skin Corr
Skin Irrit
Skin Sens
Skin sensitization
Skin Sens
Eye Dam
Eye Irrit
Schin Sensitization
Eye damage
Eye Irrit
Eye irritation

Repr Reproductive toxicity

STOT RE Specific target organ toxicity repeated exposure

Aquatic acute Aquatic short term chronic exposure Aquatic chronic Aquatic long term chronic exposure

H315 Causes skin irritation

H319 Causes serious eye irritation

P264 Wash thoroughly after handling

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352 IF ON SKIN: Wash with plenty of water.



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

09 January 2024

Page 16 of 17

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if

present and easy to do. Continue rinsing.

P321 Specific treatment (see sections 4 to 8 on this SDS and any further information on the label).

P332+P313 If skin irritation occurs: Get medical advice/attention
P337+P313 If eye irritation persists: Get medical advice/attention
P362+P364 Take off contaminated clothing and wash it before reuse

Training advice: Before using/handling the product one must read carefully present SDS.

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Component 8: Platinum® Tfi Reaction	
Buffer, 5x Skin irritation 2 H315 Eye irritation 2 H319	Calculation method

Abbreviations and acronyms:

ADR: Accord européen sur le transport des marchandises dangereuses par Route (European

CAS: Chemical Abstracts Service (division of the American Chemical Society)

CLP: Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and

mixtures

DNEL: Derived No Effect Level

EC50: Half maximal effective concentration

EINECS: European Inventory of Existing Commercial Chemical Substances

EU: European Union

GHS: Globally Harmonized System of Classification and Labeling of Chemicals

IATA: International Air Transport Association

IBC: International Bulk Code

IMDG: International Maritime Code for Dangerous Goods IOELV: Indicative Occupational Exposure Limit Value

LC50: Lethal concentration, 50 percent

LD50: Lethal dose, 50 percent

MARPOL: International Convention for the Prevention of Pollution from Ships

OEL: Occupational Exposure Level

PBT: Persistent, Bioaccumulative and Toxic

PNEC: Predicted No Effect Level

REACH: Registration, Evaluation, Authorisation and Restriction of Chemicals

SCBA: Self Contained Breathing Apparatus

SCL: Specific Concentration Limits

UN: United Nations

VPvB: Very Persistent and very Bioaccumulative

WEL: Workplace Exposure Limit

Additional information:

Concentration breakdown for BOX 1:

Concomitation broakeown for Box in			
Component 1: xTAG® CFTR PCR Mix v2	240uL	0.24 ml	0.6%
Component 2: xTAG® CFTR Bead Mix A v2	2.16mL	2.16 ml	5.7%
Component 3: xTAG® CFTR Bead Mix B v2	2.16mL	2.16 ml	5.7%
Component 4: xTAG® CFTR ASPE Mix A v2	192uL	0.192 ml	0.5%
Component 5: xTAG® CFTR ASPE Mix B v2	192uL	0.192 ml	0.5%
Component 6: xTAG® Reporter Buffer	12mLx 2 vials	24 ml	63.5%
Component 7: Platinum® Tfi Exo(-) DNA Polymerase	115uL x 3 vials	345 uL 0.345 mL	0.9%
Component 8: Platinum® Tfi Reaction Buffer, 5x	1.3mL x 4 vials	5.2 mL	13.7%
Component 9: Platinum® Tfi 50mM MgCl ₂	1mL x 3 vials	3mL	7.9%
Component 10: xTAG® Shrimp Alkaline Phosphatase	120uL x 2 vials	240 uL 0.24 ml	0.6%
Component 11: xTAG® Exonuclease I	48uL x 2 vials	96 uL 0.096 ml	0.25%



xTAG® Cystic Fibrosis (CFTR) 71 kit v2

109 January 2024

Page 17 of 17

Total volume of BOX 1: 37.825 mL

Concentration breakdown for BOX 2:

Component 12: xTAG Streptavidin, R-Phycoerythrin Conjugate - 120uL x 2 vials

Document history

Date of issue: 09 January 2024

Version no. 1

DISCLAIMER: To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.